LYTIR

Insider · SEC Form 4 · 10% Owner

Catalyst4, Inc.

In the 12 months to Nov 19, 2026, on the open market: bought $65.4M of MPLT. Filed a median of 1 business day after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $65.4M in total; Insider sales: $0 in total.Jul: Insider purchases $15.3MAug: Insider purchases $50.1MDecJanFebMarAprMayJunJulAugSepOctNov$50.1M
Insider purchases above the line: $65.4MInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. MPLTBought: MapLight Therapeutics, Inc. Aug 14, 2026 4,400,000 shares filed Aug 18, 2026 25,306,689 shares held indirectly after, as filed filing $50.1M
  2. MPLTBought: MapLight Therapeutics, Inc. Jul 30, 2026 1,000,000 shares filed Jul 30, 2026 20,906,689 shares held indirectly after, as filed filing $13.0M
  3. MPLTBought: MapLight Therapeutics, Inc. Jul 29, 2026 3,000 shares filed Jul 30, 2026 19,906,689 shares held indirectly after, as filed filing $38K
  4. MPLTBought: MapLight Therapeutics, Inc. Jul 28, 2026 206,225 shares filed Jul 30, 2026 2 transactions filing $2.3M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. MPLTCatalyst4, Inc. filed Aug 18, 2026 Schedule 13D/A may seek influence 27,536,011 shares issuer: MapLight Therapeutics, Inc. filing 49.9%
  2. MPLTCatalyst4, Inc. filed Aug 3, 2026 Schedule 13D/A may seek influence 20,906,689 shares issuer: MapLight Therapeutics, Inc. filing 47.9%